DK1740583T3 - Oxadiazolon-derivater som ppar-delta-agonister - Google Patents

Oxadiazolon-derivater som ppar-delta-agonister

Info

Publication number
DK1740583T3
DK1740583T3 DK05716233T DK05716233T DK1740583T3 DK 1740583 T3 DK1740583 T3 DK 1740583T3 DK 05716233 T DK05716233 T DK 05716233T DK 05716233 T DK05716233 T DK 05716233T DK 1740583 T3 DK1740583 T3 DK 1740583T3
Authority
DK
Denmark
Prior art keywords
ppar
delta agonists
oxadiazolone derivatives
oxadiazolone
derivatives
Prior art date
Application number
DK05716233T
Other languages
Danish (da)
English (en)
Inventor
Stefanie Keil
Wolfgang Wendler
Maike Glien
Jochen Goerlitzer
Karen Chandross
Daniel G Mcgarry
Jean Merrill
Patrick Bernardelli
Baptiste Ronan
Corinne Terrier
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1740583T3 publication Critical patent/DK1740583T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05716233T 2004-04-01 2005-03-19 Oxadiazolon-derivater som ppar-delta-agonister DK1740583T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007879A EP1586573B1 (fr) 2004-04-01 2004-04-01 Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
PCT/EP2005/002950 WO2005097786A1 (fr) 2004-04-01 2005-03-19 Derives d'oxadiazolone utilises en tant qu'agonistes delta ppar

Publications (1)

Publication Number Publication Date
DK1740583T3 true DK1740583T3 (da) 2009-10-19

Family

ID=34924545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05716233T DK1740583T3 (da) 2004-04-01 2005-03-19 Oxadiazolon-derivater som ppar-delta-agonister

Country Status (37)

Country Link
US (3) US20070179191A1 (fr)
EP (3) EP1586573B1 (fr)
JP (1) JP2007530612A (fr)
KR (1) KR20060135857A (fr)
CN (1) CN100582104C (fr)
AR (1) AR050576A1 (fr)
AT (1) ATE435225T1 (fr)
AU (1) AU2005231916A1 (fr)
BR (1) BRPI0509517A (fr)
CA (1) CA2561627A1 (fr)
CR (1) CR8572A (fr)
CY (1) CY1109370T1 (fr)
DE (2) DE602004004631D1 (fr)
DK (1) DK1740583T3 (fr)
DO (1) DOP2005000051A (fr)
EC (1) ECSP066892A (fr)
ES (1) ES2329484T3 (fr)
GT (1) GT200500028A (fr)
HR (1) HRP20090493T1 (fr)
IL (1) IL178056A0 (fr)
MA (1) MA28495B1 (fr)
MY (1) MY142431A (fr)
NO (1) NO20064981L (fr)
PA (1) PA8628701A1 (fr)
PE (1) PE20060323A1 (fr)
PL (1) PL1740583T3 (fr)
PT (1) PT1740583E (fr)
RS (1) RS51186B (fr)
RU (1) RU2374243C2 (fr)
SI (1) SI1740583T1 (fr)
SV (1) SV2006002071A (fr)
TN (1) TNSN06317A1 (fr)
TW (1) TW200602342A (fr)
UA (1) UA84203C2 (fr)
UY (1) UY28837A1 (fr)
WO (1) WO2005097786A1 (fr)
ZA (1) ZA200606870B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
ATE480536T1 (de) 2005-09-29 2010-09-15 Sanofi Aventis Derivate von 2-aminthiazolen und 2-aminooxazolen, verfahren zu deren darstellung und deren verwendung als arzneimittel
CA2624102A1 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
SI1931660T1 (sl) * 2005-09-29 2012-12-31 Sanofi Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila
CA2663115C (fr) 2006-09-08 2015-04-28 Rhode Island Hospital Traitement, prevention et elimination d'une hepatopathie alcoolique
WO2008030604A2 (fr) 2006-09-08 2008-03-13 Rhode Island Hospital Traitement, prévention et élimination d'une maladie cérébrale d'origine alcoolique
EP1932843A1 (fr) * 2006-12-14 2008-06-18 sanofi-aventis Dérivés de sulfonyl-phenyl-2H(1,2,4) oxadiazole-5-one, procédés de préparation de ceux-ci et leur usage sous forme de médicaments
WO2009149819A1 (fr) * 2008-06-09 2009-12-17 Sanofi-Aventis Pyrrolidine sulfonamides annelés avec groupement de tête oxadiazolone, procédés pour leur préparation et leur utilisation comme médicaments
MX2010013264A (es) 2008-06-09 2011-02-25 Sanofi Aventis Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas.
WO2010000353A1 (fr) * 2008-06-09 2010-01-07 Sanofi-Aventis Sulfonamides comprenant un hétérocycle et un groupe de tête oxadiazolone, procédés pour les préparer et leur utilisation comme produits pharmaceutiques
WO2010042925A2 (fr) 2008-10-10 2010-04-15 Vm Discovery Inc. Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d'autres maladies
JP5753784B2 (ja) 2008-10-10 2015-07-22 ダラ・バイオサイエンシズ，インコーポレイテッド スピカマイシン誘導体を用いて疼痛を治療又は予防する方法
CN102574823B (zh) * 2009-08-05 2014-09-10 第一三共株式会社 酰胺衍生物
JP5546543B2 (ja) * 2009-08-05 2014-07-09 第一三共株式会社 スルホン誘導体
WO2015061481A1 (fr) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Méthodes de traitement de tumeurs liquides à l'aide de compositions comprenant des dérivés de spicamycine
US20220387393A1 (en) * 2019-11-06 2022-12-08 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256680A (en) * 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW222626B (fr) * 1991-07-22 1994-04-21 Pfizer
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP0876379A1 (fr) 1996-01-17 1998-11-11 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (fr) 1999-04-16 2000-10-26 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
WO2000066585A1 (fr) 1999-04-30 2000-11-09 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
EP1204654B1 (fr) 1999-07-29 2003-07-23 Eli Lilly And Company Benzofurylpiperazines: agonistes du recepteur 5-ht2c de la serotonine
KR20020033778A (ko) 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CA2392038A1 (fr) 1999-12-03 2001-06-07 Astrazeneca Ab Forme cristalline d'acide (s)-2-ethoxy-3-[4-(2-{methanesulfonyloxyphenyl}ezhoxy)phenyl] propanoique
KR20080067009A (ko) 2000-03-31 2008-07-17 프로시디온 리미티드 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
BR0110258A (pt) 2000-04-25 2003-01-07 Kyorin Seiyaku Kk Cristal estável de derivado de tiazolidinadiona e processo para sua produção
ATE369337T1 (de) 2000-04-28 2007-08-15 Asahi Kasei Pharma Corp Neue bizyklische verbindungen
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
NZ523034A (en) 2000-06-09 2004-07-30 Aventis Pharma Gmbh Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
EP1345895B1 (fr) 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Nouvelles azetidinones 1,2-diphenyliques, leur procede de production, medicaments renfermant ces composes et leur utilisation dans le traitement de troubles du metabolisme lipidique
EP1368011A1 (fr) 2001-02-22 2003-12-10 SmithKline Beecham Corporation Methode de traitement de maladies ou de conditions induites par ppar gamma
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
AU2002333456B2 (en) 2001-08-31 2008-07-17 Sanofi-Aventis Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
US7205321B2 (en) * 2001-11-15 2007-04-17 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
US7595403B2 (en) 2003-04-01 2009-09-29 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
US7217727B2 (en) 2003-04-01 2007-05-15 Eli Lilly And Company Phospholipase inhibitors
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
SI1931660T1 (sl) * 2005-09-29 2012-12-31 Sanofi Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila

Also Published As

Publication number Publication date
DOP2005000051A (es) 2005-12-15
CR8572A (es) 2007-12-04
HK1100408A1 (zh) 2007-09-21
ECSP066892A (es) 2006-11-24
MY142431A (en) 2010-11-30
PT1740583E (pt) 2009-09-16
EP1586573A1 (fr) 2005-10-19
RU2374243C2 (ru) 2009-11-27
ES2329484T3 (es) 2009-11-26
CY1109370T1 (el) 2014-07-02
CA2561627A1 (fr) 2005-10-20
US20080262052A1 (en) 2008-10-23
UY28837A1 (es) 2005-10-31
TW200602342A (en) 2006-01-16
CN1938300A (zh) 2007-03-28
JP2007530612A (ja) 2007-11-01
PE20060323A1 (es) 2006-03-31
PL1740583T3 (pl) 2009-12-31
KR20060135857A (ko) 2006-12-29
US20070179191A1 (en) 2007-08-02
HRP20090493T1 (hr) 2009-10-31
DE602004004631D1 (de) 2007-03-22
TNSN06317A1 (en) 2007-12-03
EP1586573B1 (fr) 2007-02-07
CN100582104C (zh) 2010-01-20
AU2005231916A1 (en) 2005-10-20
US7709509B2 (en) 2010-05-04
AR050576A1 (es) 2006-11-08
WO2005097786A1 (fr) 2005-10-20
ATE435225T1 (de) 2009-07-15
UA84203C2 (en) 2008-09-25
NO20064981L (no) 2006-12-28
BRPI0509517A (pt) 2007-09-11
EP1740583B1 (fr) 2009-07-01
RS51186B (sr) 2010-10-31
EP2083006A1 (fr) 2009-07-29
SV2006002071A (es) 2006-01-30
PA8628701A1 (es) 2006-11-25
RU2006138498A (ru) 2008-05-10
DE602005015204D1 (de) 2009-08-13
ZA200606870B (en) 2008-04-30
GT200500028A (es) 2006-06-09
IL178056A0 (en) 2006-12-31
US20080255212A1 (en) 2008-10-16
MA28495B1 (fr) 2007-03-01
SI1740583T1 (sl) 2009-12-31
EP1740583A1 (fr) 2007-01-10

Similar Documents

Publication Publication Date Title
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1912991T3 (da) Xanthinderivater som selektive HM74A-Agonister
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
DK2069322T3 (da) THIOPHENDERIVATER SOM S1P1/EDG1-receptoragonister
DK2102205T3 (da) Pyridopyrazinderivater anvendelige som herbicidale forbindelser
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
DK2206710T3 (da) Indolderivater som s1p1-receptor agonister
DK2308841T3 (da) Phlorizinanaloge som SGLT2-inhibitorer
DK2225231T3 (da) Aminotriazolderivater som alx-agonister
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
DK2078001T3 (da) Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
DK1856110T3 (da) Oxyindol derivater som 5HT4-receptor agonister
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
ATE415400T1 (de) Pyrazolopyridinderivate
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer